Compare AbbVie Inc (ABBV) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Cognizant Technology Solutions Corp — how do they compare? AbbVie Inc trades at $253.85 (market cap $449.91B), while Cognizant Technology Solutions Corp trades at $43.34 (market cap $20.78B). The key difference: AbbVie Inc is far larger — about 21.7× Cognizant Technology Solutions Corp's market cap, and Cognizant Technology Solutions Corp pays the higher dividend (3%). Which is the better fit depends on your goals.
| ABBV | CTSH | |
|---|---|---|
Market Cap | $449.91B | $20.78B |
Sector | Health | Technology |
52-Week High | $261.07 | $86.70 |
52-Week Low | $184.85 | $38.73 |
Enterprise Value | $513.38B | $20.36B |
Dividend Yield | 2.72% | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Cognizant Technology Solutions (CTSH) trades at $43.94, up 4.64% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 8.97 and net margin of 10.41%, supported by $21.11B revenue in 2025. Recent news highlights AI partnerships with Google Cloud and OpenAI, positioning CTSH for growth in enterprise AI solutions.
Outlook remains positive with a consensus price target of $67.58, implying 54% upside, though near-term risks include soft IT demand and margin pressures. Institutional sentiment is mixed with 43% buy ratings, but the valuation discount and AI expansion present a compelling opportunity for long-term investors amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →
